Colon

A single patient with moderate-to-severe ulcerative colitis, weighing a JAK inhibitor against a class-wide boxed warning built almost entirely from an older rheumatoid arthritis population she does not resemble.

A single hospitalized patient with steroid-refractory acute severe ulcerative colitis, choosing a medical rescue agent against a genuine day-three deadline before colectomy becomes the default.

A single newly diagnosed patient with moderate-to-severe, high-risk Crohn's disease, testing whether early biologic therapy is worth its own risks against a step-up approach built for a milder disease course.

A single patient starting her first biologic for moderate ulcerative colitis, weighing vedolizumab's gut-selective safety profile against anti-TNF therapy's faster onset of action.

A single low-risk, immunocompetent patient with a first episode of acute uncomplicated diverticulitis, testing whether routine antibiotics still earn their place against a decade of trial evidence favoring observation alone.

A single patient with mild colonic Crohn's disease, testing whether continuing mesalamine reflects real disease control or a habit the underlying trial evidence never actually justified.

A single patient with a third recurrence of Clostridioides difficile infection, comparing a live biotherapeutic product against traditional fecal transplant after the monoclonal antibody adjunct was withdrawn from the market.

A single hospitalized patient with a first severe episode of Clostridioides difficile infection, weighing fidaxomicin's lower recurrence rate against vancomycin's far lower cost and identical short-term cure rate.

A single Crohn's disease patient losing response to infliximab, testing whether a therapeutic drug level should decide the next step before the dose is simply raised.

A single Crohn's disease patient in stable clinical remission on infliximab, testing whether checking a drug level she has no symptoms to justify is worth the cost of the test itself.

A single Crohn's disease patient in sustained deep remission on combination therapy, testing whether withdrawing the biologic, the immunomodulator, or neither is the right response to years of quiet disease.

A single newly biologic-starting Crohn's disease patient, testing whether adding a thiopurine to infliximab is worth its own risks against the immunogenicity benefit the combination is meant to provide.

A single patient on chronic opioid therapy for chronic back pain, testing whether a peripherally acting mu-opioid receptor antagonist is worth its cost once conventional laxatives have genuinely been maximized rather than simply tried.

A single patient with diarrhea-predominant irritable bowel syndrome refractory to first-line therapy, comparing rifaximin retreatment, eluxadoline, and alosetron against the specific reason each prior option failed her.

A single patient with constipation-predominant irritable bowel syndrome unresponsive to fiber and osmotic laxatives, testing which secretagogue actually fits her specific symptom pattern rather than defaulting to whichever is prescribed most often.

A single average-risk patient asking about daily aspirin for colorectal cancer prevention, testing whether a real reduction in cancer risk still justifies a real increase in bleeding risk once population-level guidance is applied to one specific person.

A single patient with new-onset microscopic colitis on a long-term NSAID, testing whether stopping the likely culprit drug or starting budesonide should come first when both are genuinely justified.

A single patient with chronic, antibiotic-refractory pouchitis after ileal pouch-anal anastomosis, testing whether another antibiotic combination is worth trying again before moving to a biologic built for a different disease.

A single patient with newly diagnosed perianal fistulizing Crohn's disease, testing whether anti-TNF therapy's decades of fistula-specific evidence still outweighs a newer IL-23-selective biologic's cleaner safety profile.

A single patient with severe, refractory late-onset diarrhea after irinotecan chemotherapy, testing whether octreotide is genuinely earned once high-dose loperamide has actually been maximized rather than simply started.

A single hospitalized patient with acute colonic pseudo-obstruction unresponsive to conservative management, testing how long conservative measures deserve before neostigmine, a drug with its own real cardiac risk, becomes the right call.

A single Crohn's disease patient who has failed anti-TNF therapy, testing whether ustekinumab's longer track record or risankizumab's narrower, more selective mechanism is the better second-line biologic for her specific disease pattern.

A single moderate-to-severe ulcerative colitis patient choosing between an oral S1P receptor modulator and a continued injectable biologic, testing whether the cardiac-monitoring requirement everyone attributes to the drug is actually in its label at all. ---